Toronto, Ontario–(Newsfile Corp. – August 24, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn), a biotechnology company developing and delivering psychedelic medicine to better treat Addiction, announced today that it has received ethical committee approval and has initiated recruitment for the first-ever study investigating ketamine in gambling addiction.


Previous articleTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida
Next articleMicrodosing LSD Makes Me a Better Mom